



Personalized Medicine in Post-COVID-19 Era

Guest Editors:

Prof. Dr. Cristian Oancea

Pulmonology Department,
University of Medicine and
Pharmacy Victor Babes,
Timisoara, Romania

Dr. Elena Cojocaru

Morpho-Functional Sciences II
Department, Faculty of Medicine,
"Grigore T. Popa" University of
Medicine and Pharmacy, Iași,
Romania

Deadline for manuscript
submissions:

15 October 2024

Message from the Guest Editors

Dear Colleagues,

Concerning the post-COVID patients, personalized medicine is of significant medical interest. The identification of biomarkers that could guide the personalized approach of these patients could allow for the identification of the most effective diagnosis and treatment methods.

The Special Issue will highlight the importance of understanding the main factors that influence individual responses to the virus and lead to more targeted and effective treatment strategies. In addition, it will focus on why certain individuals are more prone to long COVID and how to manage their symptoms more effectively. We hope that research tools such as proteomics, genomics, metabolomics and epigenomics will allow for the identification of guidelines for a personalized approach, and could help identify the patients who may need alternative vaccination strategies. Personalized medicine can help in identifying existing drugs that may be more effective for certain subgroups of COVID-19 patients, leading to potential drug repurposing for better outcomes.

Prof. Dr. Cristian Oancea

Dr. Elena Cojocaru

Guest Editors





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer
Institute, Winston-Salem, NC
27103, USA
2. Division of Hematologic
Malignancies and Cellular
Therapy, Duke University,
Durham, NC 27710, USA

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, ‘omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank: JCR - Q2 (*Medicine, General & Internal*) CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Journal of Personalized Medicine
Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/jpm
jpm@mdpi.com
[X@JPM_MDPI](https://twitter.com/JPM_MDPI)